Loading company…
Riskpilot
← Back to search
Sign in
Get full access
OmicVision Biosciences ApS
APS
Active
CVR 44285584
Ole Maaløes Vej 3, 1.
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2023
14 employees
www.omicvision.com
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 1,5M
EBITDA margin
-229.1%
Equity ratio
82.6%
Financial strength
Net profit 2024
DKK -3M
14 employees
EBITDA — year on year
DKK millions
0M
-1M
-3M
-4M
-5M
-4M
2024
Key figures
Annual report 2024
Revenue
DKK 1,5M
—
EBITDA
DKK -3,5M
—
Net profit
DKK -3M
—
Total assets
DKK 5,5M
—
Equity
DKK 4,5M
—
Employees
14
—
Company information
Legal name
OmicVision Biosciences ApS
CVR number
44285584
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. september 2023
Share capital
DKK 50.000
Employees
14 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsesformanden.
Company purpose
Selskabets formål er at drive bioteknologisk forskning og udvikling af diagnostik til kræft og andre sygdomme, samt hermed beslægtet virksomhed.
Contact
Address
Ole Maaløes Vej 3, 1.
Phone
+4526332323
Email
iummat@omicvision.com
Website
www.omicvision.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in København
All Denmark companies
Revenue
DKK millions
0M
1M
1M
2M
2M
2M
2024
EBITDA
DKK millions
0M
-1M
-2M
-3M
-5M
-4M
2024
Income statement
DKK thousands
Item
2024
Revenue
1.538
Staff expenses
-4.708
EBITDA
-3.523
Depreciation & amort.
-21
EBIT
-3.544
Net financials
113
Profit before tax
-3.431
Tax
-424
Net profit
-3.007
Balance sheet
DKK thousands
Item
2024
Total assets
5.486
Equity
4.533
Long-term debt
0
Short-term debt
953
Total debt
953
Financial ratios
5-year trend
EBITDA margin
-229.1%
This company
15.8%
Market median
-1550% vs market
2024
2024
Equity ratio
82.6%
This company
38.2%
Market median
+116% vs market
2024
2024
Return on equity
-66.3%
This company
18.4%
Market median
-460% vs market
2024
2024
Net profit margin
-195.5%
This company
8.1%
Market median
-2514% vs market
2024
2024
Asset turnover
0.28×
This company
1.12×
Market median
-75% vs market
2024
2024
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2023-09-01 – 2024-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
IT
Ishani Tara Ummat
Chief Executive Officer
Chief Executive Officer
2024
—
—
MT
Maximilian Thomas Dr Strauss
Management
Management
2023
—
—
AM
Andreas Mund
Management
Management
2023
—
—
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
OV
Ole Vorm
Chairman
2023
—
—
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
VOMA HOLDING A/S
Company
33.3%
33.3%
2024
Ummat Ventures ApS
Company
15.0%
15.0%
2024
AM Tech Ventures ApS
Company
15.0%
15.0%
2024
MS Ventures ApS
Company
15.0%
15.0%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
AM Tech Ventures ApS
OmicVision Biosciences ApS
(this company)
Board network connections
Board members of OmicVision Biosciences ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Ishani Tara Ummat
Chief Executive Officer
0 companies
Maximilian Thomas Dr Strauss
Management
0 companies
Andreas Mund
Management
0 companies
Ole Vorm
Chairman
0 companies